Biosimilar granulocyte colony-stimulating factor uptakes in the EU-5 markets: A descriptive analysis

Applied Health Economics and Health Policy

Volumn 12, Issue 3, 2014, Pages 315-326

  Bocquet, François ^a,b,c   Paubel, Pascal ^b   Fusier, Isabelle ^c   Cordonnier, Anne Laure ^c   Le Pen, Claude ^a   Sinègre, Martine ^c  

^a UNIVERSITÉ PARIS DAUPHINE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; BIOSIMILAR AGENT;

ARTICLE; COMPETITION; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG USE; FRANCE; GERMANY; HUMAN; ITALY; SPAIN; UNITED KINGDOM; ECONOMICS; EPIDEMIOLOGY; EUROPEAN UNION; STATISTICS AND NUMERICAL DATA;

BIOSIMILAR PHARMACEUTICALS; DRUG COSTS; DRUG INDUSTRY; EUROPEAN UNION; FRANCE; GERMANY; GRANULOCYTE COLONY-STIMULATING FACTOR; GREAT BRITAIN; HUMANS; ITALY; SPAIN;

EID: 84901680637     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-014-0087-8     Document Type: Article

References (49)

1. Generic medicines: essential contributors to the long-term health of society - sector sustainability challenges in Europe. IMS Health Report, 2010. http://www.egagenerics.com/index.php/publications/39-generic-medecines- essential-contributor. Accessed 27 Nov 2012.
2. Haustein R, de Millas C, Hoër A, Häussler B. Saving money in the European healthcare systems with biosimilars. Generics Biosimilars Initiat J. 2012;1(3-4):120-6.
3. Surveying tomorrow's biopharma landscape - the NASDAQ Biotech Index up close evaluate Pharma, June 2012. http://info.evaluatepharma.com/rs/ evaluatepharmaltd/images/EvaluatePharma-NBI-Up-Close-2012.pdf. Accessed 18 Oct 2013.
4. Befrits G. The case for biosimilars: a payer's perspective. Generics Biosimilars Initiat J. 2013;2(1):12.
5. Schellekens H. How similar 'biosimilars' need to be? Nat Biotechnol. 2004;22(11):1357-9.
6. What you need to know about biosimilar medicinal products: process on corporate responsibility in the field of pharmaceuticals access to medicines in Europe. European Commission. Consensus Information Paper, 2013. http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/ biosimilars-report-en.pdf. Accessed 17 Oct 2013.
7. Schellekens H, Jiscoot W. Eprex-associated pure red cell aplasia and leachates. Nat Biotechnol. 2006;24(6):613-4. (Pubitemid 43884419)
8. Hermeling S, Schellekens H, Crommelin DJ, et al. Micelle-associated protein in epoietin formulations: a risk factor for immunogenicity? Pharm Res. 2003;20:1903-7. (Pubitemid 38005518)
9. Directive 2004/27/EC of the European Parliament and of the Council of 31st March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Off J Eur Union L 136:34-57. http://eur-lex.europa.eu/en/index.htm. Accessed 21 Nov 2012.
10. Biosimilars: How much entry and price competition will result? Office of Health Economics Report based on the proceedings of an OHE Conference held on 2 June 2009 edited by Mattison N, Mestre-Ferrandiz J and Torse A, Dec. 2010. http://www.ohe.org/publications/article/biosimilars-how-much-entry-and-price- competition-will-result-13.cfm. Accessed 28 Nov 2012.
11. Rovira J, Espín J, García L et al. The impact of biosimilars' entry in the EU market. Andalusian School of Public Health Report for the European Commission (Directorate-General for Enterprise and Industry), Jan 2011. http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/ biosimilars-market-012011-en.pdf. Accessed 25 Nov 2012.
12. Godman B. Editorial: health authority perspective on biosimilars. Generics Biosimilars Initiat J. 2013;2(1):10-1.
13. Bocquet F, Paubel P. Les aspects juridiques du développement des médicaments biosimilaires. Revue de Droit Sanitaire et Social. 2012;1:121-33.
14. The global use of medicines: outlook through 2016. IMS Health for Healthcare Informatics Report, July 2012. http://www.imshealth.com/ deployedfiles/ims/Global/Content/Insights/ IMS%20Institute%20for%20Healthcare%20Informatics/ Global%20Use%20of%20Meds%202011/Medicines-Outlook-Through-2016-Report.pdf. Accessed 16 Nov 2012.
15. Kowalchyk K, Crowley-Weber C. Biosimilars: impact of differences with Hatch-Waxman. Pharm Pat Anal. 2013;2(1):29-37.
16. IMS Institute for Healthcare Informatics. MIDAS, Dec 2010.
17. Aggarwal S. What's fueling the biotech engine 2009-2010. Nat Biotechnol. 2010;28(11):1165-71.
18. IMS Health. MIDAS database. La Défense: IMS Health; 2012.
19. Bocquet F, Paubel P, Fusier I et al. Biosimilar hematopoetic growth factors in the public hospitals of Paris: trade-offs between economic goals and evidence based medicine [abstract no. PCASE5 plus poster]. International Society for Pharmacoeconomics and Outcomes Research 15th Annual European Congress; 3-7 Nov 2012, Berlin.
20. Power DA. Licensing and prescribing biosimilars in Australia. Generics Biosimilars Initiat J. 2013;2(3):152-4.
21. European public assessment reports. European Medicines Agency (EMA), 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar- search.jsp&mid=WC0b01ac058001d124. Accessed 22 Dec 2013.
22. Chauhan D, Towse A, Mestre-Ferrandiz J. The market for biosimilars: evolution and policy options, OHE Briefing No. 45, Office of Health Economics, London. 2008. http://www.ohe.org/publications/article/the-market-for- biosimilars-evolution-and-policy-options-35.cfm. Accessed 13 Oct 2013.
23. Grabowski HG, Ridley DB, Schulman KA. Entry and competition in generic biologicals. Manag Decis Econ. 2007;28(4-5):439-45.
24. Shaping the biosimilars opportunity: a global perspective on the evolving biosimilars landscape. IMS Health Whitepaper, Dec 2011. http://www.imshealth. com/ims/Global/Content/Home%20Page%20Content/IMS%20News/Biosimilars-Whitepaper. pdf. Accessed 16 Oct 2012.
25. Shaw BE, Confer DL, Hwang WY, et al. Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. Haematologica. 2011;96(7):942-7.
26. Kuderer N, DaleD, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor or febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25:3158-67. (Pubitemid 47218066)
27. Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005;10:427-37. (Pubitemid 40993570)
28. Lalami Y, Paesmans M, Aoun M, et al. A prospective randomized evaluation of G-CSF or G-CSF plus oral antibiotics in chemo-therapy-treated patients at high risk of developing febrile neutropenia. Support Care Cancer. 2004;12:725-30. (Pubitemid 39362652)
29. WHO Collaborating Centre for Drug Statistics Methodology, 2009. http://www.whocc.no/ddd/definition-and-general-considera. Accessed 30 Nov 2012.
30. Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Off J Eur Union L 136:1-33. http://eur-lex.europa. eu/en/index.htm. Accessed 23 Nov 2012.
31. WHO National Medicine Price Sources, 2010. http://www.who.int/entity/ medicines/areas/access/sources-prices/National-Medicine-Price-Sources.pdf. Accessed 15 Nov 2012.
32. IMS. Biosimilar accessible market: size and biosimilar penetration, prepared for EFPIA-EGA-EuropaBio, April 2012. http://ec.europa.eu/enterprise/ sectors/healthcare/files/docs/biosimilars-imsstudy-en.pdf. Accessed 7 Oct 2013.
33. Eurostat, Demography - National Data - Population, 2010. http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=demo-pjan&lang=fr. Accessed 15 Nov 2012.
34. Agence nationale de sécurité du médicament et des produits de santé, Répertoire des spécialités pharmaceutiques, 2013 [in French]. http://agence-prd.ansm.sante.fr/php/ecodex/ index.php. Accessed 21 Dec 2013.
35. L'assurance maladie, Base des médicaments et informations tarifaires, BdMIT, 2013 [in French]. http://www.codage.ext. cnamts.fr/codif/bdm- it/index.php?p-site=AMELI. Accessed 21 Dec 2013.
36. Declerck P, Simoens S. A European perspective on the market accessibility of biosimilars. Biosimilars. 2012;2:33-40.
37. Blackstone EA, Fuhr JP. The future of competition in the biologics market. Temple J Sci Technol Environ Law 2012; 31 L.1.
38. Galizzi MM, Ghislandi S, Miraldo M. Effects of reference pricing in pharmaceutical markets: a review. Pharmacoeconomics. 2011;29(1):17-33.
39. Garuolienè K, Godman B, Gulbinovic J, Wettermark B, Haycox A. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev Pharmacoecon Outcomes Res. 2011;11(3):343-9.
40. Puig-Junoy J. Impact of European pharmaceutical price regulation on generic price competition: a review. Pharmacoeconomics. 2010;28(8):649-63.
41. Danzon P, Ketcham J. Reference pricing of pharmaceuticals for Medicare: evidence from Germany, the Netherlands and New Zealand. Cambridge: National Bureau of Economic Research; 2004.
42. Puig-Junoy J. The impact of generic reference pricing interventions in the statin market. Health Policy. 2007;84(1):14-29. (Pubitemid 47498643)
43. National Institute for Health and Care Excellence, 2013. http://www.nice.org.uk/. Accessed 22 Dec 2013.
44. National Health Service Commissioning Board, October 2012. http://www.england.nhs.uk/wp-content/uploads/2012/09/towards-establishment.pdf. Accessed 22 Dec 2013.
45. Inspection Générale des Affaires Sociales-Inspection Générale des Finances (IGAS-IGF). Propositions pour la maîtrise de l'ONDAM, Jun 2012 [in French]. http://www. ladocumentationfrancaise.fr/rapports-publics/124000347-propositions-pour-la- maitrise-de-l-ondam-2013-2017. Accessed 22 Nov 2012.
46. Project for the Financement of Social Security Act for 2013 (in French), Senate amendment no28, 7 nov 2012. http://www.senat.fr/amendements/2012-2013/ 103/Amdt-28.html. Accessed 17 Nov 2012.
47. Moreau A, Demolis P, Cavalié C. Les médicaments biosimilaires - Etat des lieux. ANSM Report, Sep 2013 [in French]. http://www.ansm.sante.fr/var/ansm-site/storage/original/application/ 6187b427efca64d2a15e496ff691158e.pdf. Accessed 17 Oct 2013.
48. Chow S-C, Ju C. Assessing biosimilarity and interchangeability of biosimilar products under the Biologics Price Competition and Innovation Act. Generics Biosimilars Initiat J. 2013;2(1):20-5.
49. Laslop A. Biosimilar monoclonal antibodies: challenges and opportunities in Europe. Generics Biosimilars Initiat J. 2013;2(3):110-1.